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Background: Children with mucopolysaccharidoses (MPS) often have musculoskeletal (MSK) abnormalities.
Paediatric Gait, Arms, Legs, and Spine (pGALS), is a simple MSK assessment validated in school-age children to
detect abnormal joints. We aimed to identify MSK abnormalities in children with MPS performing pGALS.
Methods: Videos of children with a spectrum of MPS performing pGALS were analysed. A piloted proforma to
record abnormalities for each pGALS manoeuvre observed in the videos (scored as normal/abnormal/not
assessable) was used by three observers blinded to MPS subtype. Videos were scored independently and rescored
for intra- and inter-observer consistency. Data were pooled and analysed.
Results: Eighteen videos of children [12 boys, 6 girls, median age 11 years (4–19)] with MPS (13 type I [5 Hurler,
8 attenuated type I]; 4 type II; 1 mannosidosis) were assessed. The most common abnormalities detected using
pGALS were restrictions of the shoulder, elbow, wrist, jaw (>75% cases), and fingers (2/3 cases). Mean intra-observer
Κ 0.74 (range 0.65–0.88) and inter-observer Κ 0.62 (range 0.51–0.77). Hip manoeuvres were not clearly demonstrated
in the videos.
Conclusions: In this observational study, pGALS identifies MSK abnormalities in children with MPS. Restricted joint
movement (especially upper limb) was a consistent finding. Future work includes pGALS assessment of the hip and
testing pGALS in further children with attenuated MPS type I. The use of pGALS and awareness of patterns of joint
involvement may be a useful adjunct to facilitate earlier recognition of these rare conditions and ultimately access
to specialist care.
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The mucopolysaccharidoses (MPS) are a group of rare
inherited metabolic disorders with a spectrum of pheno-
types resulting from glycosaminoglycans accumulating
in cells due to deficiencies in the enzymes required for
their catabolism [1]. MPS are progressive multisystem
disorders ranging from attenuated to severe depending
on the degree of enzyme inactivity (Table 1). Enzyme
replacement therapy (ERT) and haematopoietic stem cell
transplant (HSCT) are available for some types of MPS,* Correspondence: h.e.foster@ncl.ac.uk
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unless otherwise stated.which may improve physical features, cognition and
function [2-4].
Musculoskeletal (MSK) abnormalities (including bone
and joint) are common across all MPS, and range from
joint contractures to deforming abnormalities of the ex-
tremities and spine [5]. MSK abnormalities commonly
present early in the course of disease and in some cases
may be the only symptoms prompting referral [6]. Though
MSK symptoms such as stiffness and joint contractures
have been noted in small series and case reports, MSK
abnormalities in MPS have yet to be evaluated by an
objective, validated tool.
The pGALS (paediatric Gait, Arms, Legs, and Spine) is
a simple, quick MSK assessment tool validated in school-
age children to detect abnormal joints [7]. pGALS was ori-
ginally developed as a basic approach for non-specialiststd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Overview of the mucopolysaccharidoses (MPS)
MPS Type Main clinical features Enzyme deficient Substrate accumulated
Skeletal disease, soft tissue storage and a range of central nervous system disease
I-H Hurler Developmental delay, coarse facial features,
dysostosis multiplex, hepatosplenomegaly,
death by age 10 years
Alpha-L-iduronidase Heparan sulfate
I-HS Hurler-Scheie Micrognathia, toe walking, moderate coarse facies,
possible normal intelligence, death by 20s
(phenotype intermediate between I-H and I-HS)
Dermatan sulfate
I-S Scheie Aortic valve disease, joint disease, corneal clouding,
normal facies, survive into adulthood
II Hunter Severe: Disease course similar to MPS I-H,
but clear corneas, aggressive behaviour
and developmental delay
Iduronate sulfatase Heparan sulfate
Mild: Normal or near-normal intelligence,
less pronounced physical features
Dermatan sulfate
MPS VII Sly Variable intermediate presentation similar to MPS I,
from fetal hydrops to mild dysmorphism;
dense inclusions in granulocytes
Beta-glucuronidase Heparan sulfate
Dermatan sulfate
MPS VI Maroteaux-Lamy Similar to MPS I without CNS disease,
pachymeningitis cervicalis, death in teens and 20s;
Hurler phenotype with marked corneal clouding;
mild, moderate and severe expression in different families
N-acetylgalactosamine-4-sulfatase
(arylsulfatase B)
Dermatan sulfate
Skeletal, cartilage and ligament disease primarily
MPS IVA Morquio A Skeletal disease (bone dysplasia) with short stature,
ligamentous laxity, corneal opacities, final height <125 cm
N-acetylgalactosamine-6-sulfatase Keratan sulfate
MPS IVB Morquio B Same as IV-A but milder; adult height >120 cm Beta-galactosidase
MPS IX Natowicz syndrome Periarticular masses, nodular synovium,
popliteal cyst, large joint effusion
Hyaluronidase 1 Hyaluronan
MPS IIIA Sanfilippo A Behavioural problems, sleeping disorder, aggression,
progressive dementia, mild dysmorphism, coarse hair,
clear corneas, survival to adulthood possible
Sulfamidase Heparan sulfate
MPS IIIB Sanfilippo B Alpha-N-acteylglucosaminidase
MPS IIIC Sanfilippo C GAC-acteylase
MPS IIID Sanfilippo D N-acetylglucosamine-6-sulfatase
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and Spine (GALS) examination for adult patients
[8]. pGALS consists of three questions about pain and
function, followed by a series of simple manoeuvres to
assess all major joints to discern normal from abnormal
(http://www.arthritisresearchuk.org/health-professional-
s-and-students/video-resources/pgals.aspx). Abnormal-
ities on pGALS can be followed through with a more
detailed regional joint examination and a consensus
approach is available [9]. The aim of this study was to
describe the use of pGALS in a group of children with
established MPS and to assess MSK abnormalities
observed.
Methods
Videos of children with a spectrum of MPS performing
pGALS were made at a specialist MPS centre in the UK,
by a specialist physiotherapist (PH) as part of their rou-
tine care prior to, and independent of, the current study.
Informed consent for the use of the videos for teaching
and research was obtained. Anonymised patient data(age at the time of the video recording, gender, MPS
subtype, history of ERT or HSCT) were made available
to the research team. Although historically the terms
MPS type I Hurler-Scheie and Scheie syndrome have
been used to describe children with more attenuated fea-
tures of MPS type I, there are no specific criteria for
classification of these MPS forms which are regarded as
a spectrum of phenotypes. For the purpose of this study,
children with MPS type I Hurler-Scheie or Scheie were
classified as attenuated MPS type I.
A piloted proforma included the 25 manoeuvres that
make up pGALS. The proforma was piloted with videos
of two children performing pGALS (one child with ju-
venile idiopathic arthritis and another with MPS) by four
observers (MC, ES, EH and HF) to achieve consensus
with definitions for normal/abnormal/not assessable for
each of the 25 pGALS manoeuvres. A manoeuvre was
considered “not assessable” if it was not performed com-
pletely or not clearly observed on video footage. Specific
comment on adequate exposure and completion of the
manoeuvres was available in a column designated for
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sess each video independently by three observers (MC,
ES, EH), who were blinded to the MPS subtype. The ob-
servers included a paediatric rheumatologist (MC), a
paediatric rheumatology trainee (ES) and a specialist
paediatric rheumatology physiotherapist (EH). One ob-
server (MC) scored five videos twice on two separate oc-
casions one week apart.
Data were pooled and analysed using descriptive statis-
tics. Percentage scores for the number of abnormal
manoeuvres were calculated taking into account three
separate scores per manoeuvre per child. The number
of abnormal observations per manoeuvre served as
a numerator and the total number of committed
observations per manoeuvre as denominator (manoeu-
vres considered “not assessable” were not included inTable 2 Musculoskeletal abnormalities detected by pGALS (n
Manoeuvre tested pGALS instruction All MPS
1203 t
Shoulder abduction,
external rotation
Hands behind neck
Shoulder flexion Reach arms up
Wrist flexion Hands together back to back
Elbow extension Reach up
TMJ excursion Open mouth wide and try to
put 3 fingers inside
MCP, DIP, PIP extension Hands and wrists together
Forward flexion of spine Bend forwards. Observe curvature
of spine from all sides
Spinal deformity Observe patient standing and
then bending forwards
Gait Observe patient walking
Wrist extension Hands palm to palm
MCP/DIP/PIP extension Hands out in front
Cervical spine lateral flexion Touch ear to shoulder
Elbow extension Hands out in front
Ankle dorsiflexion Walk on heels
Neck extension Look up to the ceiling
Forearm supination Turn hand over
Opposition of thumb
and 3rd-5th fingers
Touch tips of fingers with thumb
MCP/DIP/PIP flexion Make a fist
Elbow flexion Put hands behind neck
Knee extension Bring ankle up to bottom
Knee flexion
Opposition of thumb
and index finger
Touch tip of finger with thumb
Elbow flexion Put hands and wrists together
Ankle plantar flexion Walk on tip-toes
Key: DIP = distal interphalangeal; MCP =metacarpophalangeal; PIP = proximal inte
TMJ = temporomandibular joint.the denominator). Thus, if all four children with MPS
type II were noted to have abnormal shoulder flexion,
this would mean all three observers noted the same ab-
normality for all four children i.e. 12 out of 12 scores (3
per each of 4 children) were abnormal. Median ReCal2
programming [10] was used to calculate Kappa scores
for inter- and intra-observer consistency.
Results and discussion
Eighteen videos of children with MPS were assessed by
three observers, i.e., a total of 54 sets of ratings and a
maximum of 54x25 = 1350 potential scores; 1203 assess-
able manoeuvres scored. The patient group included 12
boys and six girls with a median age of 11 years at the
time of the video recording (range 4–19 years). MPS
subtypes included: 13 MPS type I (five MPS type Iumber of abnormal observations to total observations)
(n = 18 patients)
otal observations
MPS I
(n = 13)
MPS II
(n = 4)
Mannosidosis (n = 1)
49/54 (91%) 35/39 (90%) 12/12 (100%) 2/3 (67%)
48/54 (89%) 36/39 (93%) 12/12 (100%) 0/3 (0%)
41/54 (76%) 27/39 (69%) 12/12 (100%) 2/3 (67%)
39/53 (74%) 26/39 (90%) 12/12 (100%) 1/2 (50%)
39/54 (72%) 28/39 (72%) 10/12 (83%) 1/3 (33%)
37/54 (69%) 24/39 (62%) 11/12 (92%) 2/3 (67%)
31/50 (62%) 21/35 (60%) 8/12 (67%) 2/3 (67%)
28/45 (62%) 22/34 (65%) 5/9 (56%) 1/2 (50%)
28/45 (62%) 20/32 (63%) 7/10 (70%) 1/3 (33%)
33/53 (60%) 22/39 (56%) 11/11 (100%) 0/3 (0%)
29/52 (56%) 17/37 (46%) 12/12 (100%) 0/3 (0%)
29/53 (55%) 17/38 (45%) 12/12 (100%) 0/3 (0%)
22/40 (55%) 12/27 (44%) 9/11 (82%) 1/2 (50%)
24/45 (53%) 15/33 (45%) 7/9 (78%) 2/3 (67%)
28/53 (53%) 19/38 (50%) 9/12 (75%) 0/3 (0%)
20/42 (48%) 10/30 (33%) 9/11 (82%) 1/1 (100%)
23/54 (43%) 14/39 (36%) 8/12 (67%) 1/3 (33%)
20/54 (37%) 10/39 (26%) 10/12 (83%) 0/3 (0%)
12/42 (29%) 6/27 (33%) 5/12 (42%) 1/3 (33%)
12/44 (27%) 7/29 (24%) 4/12 (33%) 1/3 (33%)
11/45 (24%) 4/30 (13%) 7/12 (58%) 0/3 (0%)
10/54 (19%) 5/39 (13%) 5/12 (42%) 0/3 (0%)
7/53 (13%) 5/39 (13%) 2/11 (18%) 0/3 (0%)
4/45 (9%) 2/33 (6%) 2/9 (22%) 0/3 (0%)
rphalangeal; pGALS = paediatric Gait, Arms, Legs and Spine;
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and one child with mannosidosis (see Table 2). All chil-
dren with MPS II had attenuated disease without pro-
gressive central nervous system involvement. As such,
although their IQ was at the lower end of normal, or
considered to have a mild intellectual disability, they
were able to follow the instructions as deemed by their
attempts at the manoeuvres fairly well. Fourteen chil-
dren had received ERT, of which one had also received
an HSCT. Four children had not received any therapy
(three MPS type II, one MPS type I).
Table 2 summarises the abnormalities detected using
pGALS for the whole patient group and then according
to MPS subtypes. In the majority, all the manoeuvres
were scored by all observers, although hip manoeuvres
were difficult to assess as some children were not un-
dressed or the views were obscured. For the whole group
of children, restriction of joint movement was frequently
seen and in order of descending frequency, the most
commonly affected joints were in the upper limb (shoul-
ders, wrists, elbows, fingers), temporomandibular joints
(TMJs), neck and lower limbs (ankles and knees). HipTable 3 Musculoskeletal abnormalities detected by pGALS in
Manoeuvre tested p
Spinal deformity
Shoulder flexion
TMJ excursion Open mouth w
Forward flexion of spine Bend forwards. Obs
Shoulder abduction, external rotation H
Wrist flexion Hands
Elbow extension
Gait Ob
MCP, DIP, PIP extension Hand
Neck extension Lo
Wrist extension H
MCP/DIP/PIP extension H
Ankle dorsiflexion
Elbow extension H
Cervical spine lateral flexion To
Forearm supination
Opposition of thumb and 3rd-5th fingers Touch t
Knee extension Brin
Knee flexion
Elbow flexion Pu
Elbow flexion Put ha
Ankle plantar flexion
MCP/DIP/PIP flexion
Opposition of thumb and index finger Touch
Figures stated as number of abnormal observations to number of total observationevaluation as per pGALS maneouvre was not performed
in the videos or the video footage did not include ad-
equate views to assess hip movement. Gait was abnor-
mal in many children with free text comments made
about toe walking, slow walking, or unstable gait. At
each joint, specific movements were more commonly
abnormal than others – for example at the shoulder
(forward flexion and abduction/external rotation (90%)),
elbow (extension 72%), wrist (flexion 74%), fingers (ex-
tension 67%), temporomandibular joint excursion (70%),
spine (forward flexion 62%), and ankles (dorsiflexion
52%). Spinal deformity was visible in 61%.
All components of the pGALS manoeuvres demon-
strated abnormalities. The three manoeuvres most likely
to demonstrate joint abnormalities were, “Raise your
hands straight in the air to the sky”, “Put your hands to-
gether back to back”, “Put your hands behind your neck”,
(See Table 2, italicized text). Observing gait, spine and for-
ward spinal flexion were also informative. Some children
(17%, n = 3) had difficulty with walking and especially
walking on their heels or toes and two (11%) had genu val-
gum. Free text comments included observations of shortMPS type I (Hurler)
GALS instruction MPS I (Hurler) (n = 5)
15/15 (100%)
Reach arms up 13/15 (87%)
ide and try to put 3 fingers inside 13/15 (87%)
erve curvature of spine from all sides 11/15 (73%)
ands behind neck 11/15 (73%)
together back to back 10/15 (67%)
Reach up 9/15 (60%)
serve patient walking 9/15 (60%)
s and wrists together 8/15 (53%)
ok up to the ceiling 7/15 (47%)
ands palm to palm 6/15 (40%)
ands out in front 6/15 (40%)
Walk on heels 6/15 (40%)
ands out in front 4/11 (36%)
uch ear to shoulder 5/15 (33%)
Turn hand over 4/12 (33%)
ips of fingers with thumb 4/15 (27%)
g ankle up to bottom 2/14 (14%)
1/15 (7%)
t hands behind neck 1/15 (7%)
nds and wrists together 1/15 (7%)
Walk on tip-toes 0/15 (0%)
Make a fist 0/15 (0%)
tip of finger with thumb 0/15 (0%)
s.
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aids (17%, n = 3), dysmorphism (89%, n = 16), dental ab-
normalities (6%, n = 1), and short, thickened fingers (28%,
n = 5).
Patterns of joint abnormalities were analysed by MPS
subtype (Tables 3, 4 and 5). With respect to the different
MPS subtypes, the same pattern of joint involvement
was apparent using pGALS and in decreasing order of
frequency, restriction of shoulders, wrists, elbows, fin-
gers, TMJs and spine were most common. Gait and
spinal appearance were also commonly abnormal. These
abnormalities were more frequent in MPS II compared
to the MPS I. Dysmorphism was observed in all MPS
type I Hurler and II patients and noted to be mild in the
majority [n = 7, 88%] of the MPS attenuated type I pa-
tients. Manoeuvre-specific difficulties arose with asking
children to put three fingers into their mouths, and ask-
ing children to make a fist, both of which required re-
peat instructions in some patients. Physically difficult
manoeuvres for some children included walking and
bending over (spinal flexion), which children would at-
tempt but be unable to perform completely or performTable 4 Musculoskeletal abnormalities detected by pGALS in
Manoeuvre tested
Shoulder abduction, external rotation
Shoulder flexion
Elbow extension
Wrist flexion H
Wrist extension
MCP, DIP, PIP extension H
Gait
TMJ excursion Open mout
Spinal deformity
Forward flexion of spine Bend forwards.
Neck extension
Cervical spine lateral flexion
MCP/DIP/PIP extension
Elbow extension
Ankle dorsiflexion
MCP/DIP/PIP flexion
Opposition of thumb and 3rd-5th fingers Tou
Elbow flexion
Forearm supination
Knee extension
Knee flexion
Opposition of thumb and index finger Tou
Elbow flexion Pu
Ankle plantar flexionvery slowly. This was more apparent in those with pro-
nounced contractures and skeletal abnormality.
Abnormalities on pGALS varied with age. Younger chil-
dren ages 0–10 years (n = 9, 27 observations), in compari-
son to older children ages 11–19 (n = 9, 27 observations)
were observed to have fewer dysmorphic features (52%
[12/23] younger versus 80% [20/25] older), restriction of
shoulder flexion and abduction (83% [20/24] and 85% [23/
27] versus 96% [26/27] and 100% [27/27]), TMJ excursion
(67% [18/27] versus 81% [22/27]), MCP extension (73%
[19/26] versus 85% [22/26]) and spinal deformities (54%
[14/26] versus 68% [13/19]). All other manoeuvres yielded
<50% abnormal scores. All but one of these children had
received ERT treatment. Children ages 11–19 were all
noted to be dysmorphic. Seven children had received ERT,
with one having also received an HSCT.
Consistency between observers was very good with a
mean intra-observer Kappa 0.74 (range 0.65-0.88) and a
mean inter-observer Kappa 0.62 (range 0.51-0.77). No
apparent discordance in agreement was noted.
This is the first study to describe MSK abnormalities
in children with MPS using pGALS as a standardizedMPS attenuated type I
pGALS instruction MPS Ia (n = 8)
Hands behind neck 24/24 (100%)
Reach arms up 23/24 (96%)
Reach up 17/24 (71%)
ands together back to back 17/24 (71%)
Hands palm to palm 16/24 (67%)
ands and wrists together 16/24 (67%)
Observe patient walking 11/17 (65%)
h wide and try to put 3 fingers inside 15/24 (62%)
7/19 (56%)
Observe curvature of spine from all sides 10/19 (53%)
Look up to the ceiling 12/23 (52%)
Touch ear to shoulder 12/23 (52%)
Hands out in front 11/22 (50%)
Hands out in front 8/16 (50%)
Walk on heels 9/18 (50%)
Make a fist 10/24 (42%)
ch tips of fingers with thumb 10/24 (42%)
Put hands behind neck 5/12 (42%)
Turn hand over 6/18 (33%)
Bring ankle up to bottom 5/15 (33%)
3/15 (20%)
ch tip of finger with thumb 5/24 (21%)
t hands and wrists together 4/24 (17%)
Walk on tip-toes 2/18 (11%)
Table 5 Musculoskeletal abnormalities detected by pGALS in MPS type II
Manoeuvre tested pGALS instruction MPS II (n = 4)
Shoulder flexion Reach arms up 12/12 (100%)
Shoulder abduction, external rotation Hands behind neck 12/12 (100%)
Elbow extension Reach up 12/12 (100%)
Wrist flexion Hands together back to back 12/12 (100%)
Wrist extension Hands palm to palm 11/11 (100%)
MCP/DIP/PIP extension Hands out in front 12/12 (100%)
Cervical spine lateral flexion Touch ear to shoulder 12/12 (100%)
MCP, DIP, PIP extension Hands and wrists together 11/12 (92%)
TMJ excursion Open mouth wide and try to put 3 fingers inside 10/12 (83%)
MCP/DIP/PIP flexion Make a fist 10/12 (83%)
Elbow extension Hands out in front 9/11 (82%)
Forearm supination Turn hand over 9/11 (82%)
Ankle dorsiflexion Walk on heels 7/9 (78%)
Neck extension Look up to the ceiling 9/12 (75%)
Gait Observe patient walking 7/10 (70%)
Forward flexion of spine Bend forwards. Observe curvature of spine from all sides. 8/12 (67%)
Opposition of thumb and 3rd-5th fingers Touch tips of fingers with thumb 8/12 (67%)
Spinal deformity 5/9 (56%)
Opposition of thumb and index finger Touch tip of finger with thumb 5/12 (42%)
Elbow flexion Put hands behind neck 5/12 (42%)
Knee extension Bring ankle up to bottom 4/12 (33%)
Knee flexion 7/12 (58%)
Ankle plantar flexion Walk on tip-toes 2/9 (22%)
Elbow flexion Put hands and wrists together 2/11 (18%)
Figure Key: ANA = antinuclear antibody; ESR = erythrocyte sedimentation rate; IDUA = iduronidase, alpha-L; JIA = juvenile idiopathic arthritis; NSAIDs = non-steroidal
anti-inflammatory drugs; pGALS = paediatric Gait, Arms, Legs and Spine; RA = rheumatoid arthritis; uGAG= urinary glycosaminoglycans.
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strate that pGALS performs well to identify abnormal
joints with joint restriction with the upper limbs, TMJ,
neck and spine being the most commonly observed pat-
tern of joint involvement. We demonstrate that pGALS
is able to discern a consistent pattern of joint involve-
ment across various MPS subtypes with changes being
more marked in MPS type II compared to the attenu-
ated MPS type I. We observed that pGALS also per-
forms well in attenuated MPS type I, including younger
children. This is important since these children often
present with MSK features, invariably subtle and in iso-
lation from other system involvement, resulting in sig-
nificant delay in diagnosis [11].
The MSK abnormalities observed using pGALS are
similar to those cited in the literature with marked and
widespread joint restriction with preferential involve-
ment of the upper limbs, most notably the shoulders
[12] and interphalangeal joints causing fixed flexion de-
formities in the fingers [5,6]. Our patient group had a
large spectrum of ages and in the younger children withthe attenuated subtype, predominant involvement of the
upper limb was observed. We cannot comment fully on
lower limb contractures as hip involvement was not ad-
equately assessed. Limited TMJ excursion was common
and may reflect true joint damage, the presence of “bul-
let phalanges” (large, round fingers observed in some
children with MPS), or oral crowding as a result of
macroglossia or dental abnormalities [13].
There are several limitations to our study. Firstly, the
number of children included was relatively small and did
not represent all subtypes of MPS. Given the rarity of
MPS, however, we consider the study to present clinic-
ally important findings. Secondly, this was a retrospect-
ive assessment of videos recorded as part of routine
clinical assessment at a specialist MPS centre in the UK;
the available videos did not provide adequate views
of hip assessment in some cases and the videos had
been edited. Consequently it was not clear how many
attempts were needed, whether the instructions to the
children were fully understood and we were not able to
evaluate the time taken to perform manoeuvres. There
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in an additional cohort of children, particularly with re-
spect to hip assessment. Thirdly, the group of children
were not incident cases and many had established disease.
It is therefore not possible to comment on the utility of
pGALS in detecting previously undiagnosed disease. ItFigure 1 Suggested Revisions (highlighted yellow with asterisk*) to E
Adapted from Cimaz et al. [17].was, however, able to discern abnormal joints even in the
younger children with milder forms of MPS and in par-
ticular the attenuated phenotype.
The pGALS examination was originally developed in
the context of paediatric rheumatology clinics but has
been shown to be useful to detect pathology other thanxisting Algorithm for Evaluation of Joint Contractures in Children.
Chan et al. Pediatric Rheumatology 2014, 12:32 Page 8 of 9
http://www.ped-rheum.com/content/12/1/32rheumatic disease in acute general paediatric assessment
[14,15]. Furthermore pGALS has been shown to detect
joint abnormalities that may not be apparent from his-
tory alone [16]. Our study suggests that pGALS may be
a useful adjunct to facilitate earlier recognition of MPS
and this is of clinical importance as a large number of
children in this study had attenuated MPS type 1. Such
patients often present with subtle contractures and de-
lays in diagnosis [11,17]. Given the availability of ERT,
this delay is concerning as early intervention is likely
to improve the clinical outcomes for these children. It is
increasingly important to develop strategies to facilitate
early diagnosis and the algorithmic approach to evalu-
ation of the child with joint contractures is welcome
[17] [See Figure 1].
Conclusions
Our study suggests that pGALS may be an effective tool
to detect MSK changes, including joint contractures and
the characteristic pattern of joint involvement in MPS.
Further work is needed to validate our findings and
develop educational strategies to facilitate recognition
of MPS, access to specialist care and ultimately improve
clinical outcomes.
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